News - Appointments

Erich Schlick, a venture capitalist and industrialist, has been appointed chair of the board of directors of Switzerland-based NBE-Therapeutics GmbH which is developing antibody-drug conjugates. He is currently a general partner and managing director at Wellington Partners in Munich.

Nordic Nanovector ASA has appointed Christine Wilkinson Blanc as chief medical officer to help it advance its portfolio of targeted cancer therapies.

Peter Selin, an experienced business development executive, has been appointed chief business officer at Oasmia Pharmaceutical AB, a Swedish specialty pharma company.

Thomas Burt, a venture capitalist, has become a non-executive director at Redx Pharma Plc, representing the Sofinnova Crossover Fund, a recent investor. Mr Burt has been a partner in the fund since its inception in 2017.

The France-based vaccine company Valneva SE has appointed Juan Carlos Jaramillo as chief medical officer, effective 1 October, to lead the company’s portfolio of preventive treatments against Lyme disease, chikungunya and SARS-COV-2.

Paul Higham, an experienced manager, has joined Valo Therapeutics Ltd as chief executive to lead the company through a new financing round and help take its first oncolytic virus compound into the clinic.

Mission Therapeutics Ltd, which is developing small molecule drugs for neurodegenerative disorders, has promoted Paul Thompson to the position of chief scientific officer, and Nick Edmunds to chief technology officer. The two executives joined Mission in 2016 and 2018 respectively.

CureVac BV, which is developing a messenger RNA (mRNA) vaccine for Covid-19, has appointed Franz-Werner Haas as chief executive and Igor Splawski as chief scientific officer. Both appointments come as the candidate vaccine progresses in the clinic.

Autolus Therapeutics Plc, which is developing cellular immunotherapies for cancer, has appointed Jay Backstrom to its board of directors, and promoted Nushmia Khokhar to senior vice president for clinical development and drug safety. Dr Khokhar joined Autolus in 2017.

The British biotechnology company Mogrify Ltd has appointed Lorenz Mayr to its board of directors. Mogrify works on the development of cell therapies through the discovery of novel cell conversions.